Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide
Author:
Chernov Alexandr N.12ORCID, Alaverdian Diana A.3ORCID, Glotov Oleg S.1, Talabaev Michael V.4, Urazov Stanislav P.1, Shcherbak Sergei G.1, Renieri Alessandra35, Frullanti Elisa3, Shamova Olga2
Affiliation:
1. Department of Clinics and Genetics Investigations , Saint Petersburg City Hospital No40 of Resort District , Saint Petersburg , Russian Federation 2. Laboratory of Design and Synthesis of Biologically Active Peptides, Department of General Pathology and Pathophysiology , Institute of Experimental Medicine , Saint-Petersburg , Russian Federation 3. Medical Genetics, Department of Medical Biotechnologies , University of Siena , Siena , Italy 4. Department of Pediatric Neurosurgery , Republican Center for Neurology and Neurosurgery , Minsk , The Republic of Belarus 5. Genetica Medica , Azienda Ospedaliera Universitaria Senese , Siena , Italy
Abstract
Abstract
Objectives
Oncological diseases are an urgent medical and social problem. The chemotherapy induces not only the death of the tumor cells but also contributes to the development of their multidrug resistance and death of the healthy cells and tissues. In this regard, the search for the new pharmacological substances with anticancer activity against drug-resistant tumors is of utmost importance. In the present study we primarily investigated the correlation between the expression of TrkA and p75 receptors with the nerve growth factor (NGF) and cisplatin or temozolomide sensitivity of anaplastic astrocytoma (AA), glioblastoma (GB) and medulloblastoma (MB) cell cultures. We then evaluated the changing of copy numbers of MYCC and MYCN and its correlation with cytotoxicity index (CI) in MB cells under NGF exposition.
Methods
The primary cell cultures were obtained from the tumor biopsy samples of the patients with AA (n=5), GB (n=7) or MB (n=25) prior to radiotherapy and chemotherapy. The cytotoxicity effect of NGF and its combinations with cisplatin or temozolomide, the relative expression of TrkA and p75 receptors, its correlations with CI in AA, GB and MB primary cell cultures were studied by trypan blue cytotoxicity assay and immunofluorescence staining respectively. The effect of NGF on MYCC and MYCN copy numbers in MB cell cultures was studied by fluorescence in situ hybridization.
Results
We found that the expression of TrkA and p75 receptors (p=0.03) and its ratio (p=0.0004) depends on the sensitivity of AA and GB cells to treatment with NGF and its combinations with cisplatin or temozolomide. NGF reduces (p<0.05) the quantity of MB cells with six or eight copies of MYCN and three or eight copies of MYCC. Besides, NGF increases (p<0.05) the quantity of MB cells containing two copies of both oncogenes. The negative correlation (r=−0.65, p<0.0001) is established between MYCC average copy numbers and CI of NGF in MB cells.
Conclusions
The relative expression of NGF receptors (TrkA/p75) and its correlation with CI of NGF and its combinations in AA and GB cells point to the mechanism involving a cell death signaling pathway. NGF downregulates (p<0.05) some increased copy numbers of MYCC and MYCN in the human MB cell cultures, and upregulates normal two copies of both oncogenes (p<0.05).
Funder
Belarusian Republican Foundation for Fundamental Research projects National Academy of Sciences of Belarus for graduate students
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference52 articles.
1. Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492. 2. International Agency for Research on Cancer (Globocan) World Health Organization. Access mode. Available from: https://gco.iarc.fr/tomorrow/home Data mode 05.18.2020. 3. Azzarelli, R, Simons, BD, Philpott, A. The developmental origin of brain tumours: a cellular and molecular framework. Development. 2018;145.pii:dev162693. https://doi.org/10.1242/dev.162693. 4. Jakobsen, JN, Urup, T, Grunnet, K, Toft, A, Johansen, MD, Poulsen, SH, et al. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. J Neuro Oncol 2018;137:439–46. https://doi.org/10.1007/s11060-017-2736-x. 5. Penas-Prado, M, Hess, KR, Fisch, MJ, Lagrone, LW, Groves, MD, Levin, VA, et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 2015;17:266–73. https://doi.org/10.1093/neuonc/nou155.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|